Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a BA from Harvard University and an MBA from Harvard Business School.
Dr. Elliot Goldstein
Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies. Dr. Goldstein holds an MD from the University Aix-Marseille II, Marseille, France, and a BSc from McGill University, Montreal.
Dr. Neil Cashman
Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Johanne Kaplan, PhD
Johanne Kaplan is a former VP of Research at Sanofi Genzyme. Over the course of her 23-year career at Genzyme, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, cancer immunotherapy and autoimmunity. Most recently, as VP of Neuroimmunology Research, Dr. Kaplan led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program. Her work has resulted in over 70 scientific publications and multiple patents. Dr. Kaplan holds a PhD in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York, USA.
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm providing finance, operations and strategic support to life science companies. He brings more than 30 years of experience in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and several privately held life science companies, in addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Cabaletta Bio, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc. He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
Gavin T. Malenfant
Gavin joins ProMIS Neuroscience bringing more than 30 years of biopharmaceutical industry experience to this position. Prior to ProMIS Neurosciences Gavin operated his own consulting business for series A companies to develop strategies and drive execution resulting in successful IPO’s. Before consulting, Gavin was head of operations for Sarepta where he led the integration of functions in support of approval and commercial launch of EXONDYS 51. All these experiences are backed by nearly twenty-years with Genzyme, leading the rare disease program management organization and head of operations for research and development, culminating in the successful U.S. and E.U approvals and launches of Aldurazyme®, Myozyme® and Cerdelga.
Ernest D. Bush, PhD
Dr. Bush has 35 years of experience working in the field of biomedical R&D, driving development of innovative therapies for treatment of human diseases. He has served as a consultant in non-clinical development providing advice and insight into IND enabling programs, pre-clinical data-set analysis for due diligence and prioritization of investment decisions, and evaluation and audits of GLP bioanalytical and toxicology facilities and studies. In recent years, Dr. Bush has served as Chief Scientific Officer at Akashi Therapeutics, Inc., providing expertise to the development of drugs in Duchene Muscular Dystrophy. In previous positions, Dr. Bush worked as Senior Research Director and Head of Non-Clinical Drug Safety at Hoffmann-La Roche, Inc. where among other duties he led the assembly and review of preclinical data packages for all potential in-licensing and acquisition drug candidates and companies. He has utilized this experience to help small pharmaceutical companies and non-profit patient advocacy organizations plan and execute strategies to move them forward expeditiously and cost-effectively. Dr. Bush received his PhD in Medicinal Chemistry from the University of Washington, and an MS in Chemistry and a BA in General Sciences from the University of Oregon.
Dennis Chen, PhD
Denis Chen is a Principal Consultant at BioDev Consulting LLC. In this expert role, Dennis provides Regulatory, Affairs, Chemistry, Manufacturing & Controls (CMC) and Biopharmaceutical Development consulting services to ProMIS with expertise in peptides, proteins and oligonucleotides. Dennis’ expertise includes preformulation, formulation and analytical development, parenteral and sustained release delivery, manufacturing and management of clinical supplies and pharmaceutical products.
Dennis has over 25 years of prior pharmaceutical experience in working with companies from virtual to global and all phases from preclinical to post-approval. Prior to taking on his expert consultant role, Dennis was Director of Regulatory Affairs CMC at Intarcia Therapeutics and prior to that was Director of Process Development & Manufacturing at the Geron Corporation.
Michael Grundman, MD, MPH
Dr. Grundman previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy, LLC and Elan Pharmaceuticals, Inc. Prior to joining the pharmaceutical industry, Dr. Grundman was Associate Director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD) and is currently an Adjunct Professor of Neurosciences at UCSD. He received his BA from New York University with Honors in Biochemistry. He obtained an MD and Neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University. Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee and is an inventor on a number of patents related to Alzheimer’s disease therapy. He lectures frequently at national and international scientific meetings and has published over 60 articles related to Alzheimer’s disease and dementia.
Dr. David Wishart
Dr. David Wishart is a Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and with the Department of Pathology and Laboratory Medicine. He has been with the University of Alberta since 1995. Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches. These experimental approaches include NMR spectroscopy, circular dichroism, fluorescence spectroscopy, electron microscopy, protein engineering and molecular biology. The computational methods include molecular dynamics, agent-based modeling, bioinformatics and machine learning. Over the course of his career, Dr. Wishart has published more than 430 scientific papers covering many areas of protein science including structural biology, protein metabolism and computational biochemistry. These papers have been cited more than 78,000 times. Dr. Wishart has been awarded research grants totaling more than $130 million from a number of funding agencies including CIHR, NSERC, NIH, Genome Canada, CFI, NRC, APRI, PrioNET, PENCE and Compute Canada. Dr. Wishart has also led or directed a number of core facilities and centres including the Canadian Bioinformatics Help Desk, the PENCE bioinformatics core facility, the NRC Nano Life Sciences Division, the PrioNet Prion Protein and Plasmid Production Facility, and the Pan-Alberta Metabolomics Platform (PANAMP). Dr. Wishart currently co-directs The Metabolomics Innovation Centre (TMIC), Canada’s national metabolomics laboratory. Dr. Wishart held the Bristol-Myers Squibb Research Chair in Pharmaceutical Sciences from 1995-2005, received the Astra-Zeneca-CFPS Young Investigator Prize in 2001, was awarded a Lifetime Honorary Fellowship by the Metabolomics Society in 2014 and elected as a Fellow of the Royal Society of Canada in 2017. Dr. Wishart has been identified as one of the world’s most highly cited scientists for each of the past 7 years.
Board of Directors
Dr. Neil Cashman
(bios already under Management Team)
Richard Gregory joined ImmunoGen as Chief Scientific Officer & Executive VP for Research in January of 2015. In this capacity he provides leadership and direction to the Research organization and is responsible for the generation of development candidates based upon ImmunoGen’s Antibody Drug Conjugate technology. Prior to ImmunoGen, Richard held a variety of roles at Genzyme and Sanofi-Genzyme, including Vice President for Gene Therapy, Head of Corporate Research and Head of R&D for the Sanofi/Genzyme R&D Center. Rich received his BSc in Biochemistry from Virginia Tech, his PhD in Biochemistry from the University of Massachusetts, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.
Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his BA in Economics (First Class Standing) from the University of Alberta in 1978 followed by his JD from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton Alberta.
Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. He is also a co-founder and board member for Vico Therapeutics, an oligonucleotide-based RNA modulating Company focused on developing therapeutics for patients suffering from rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise, overseeing seminal investments to enter the ophthalmology field and advancing Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.
Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.
Maggie has almost 30 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries. She holds a B.A. in Biology from University of California, a Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences and a J.D. summa cum laude from New York Law School. After spending 8 years at the boutique IP firm of Fish & Neave in New York, Maggie spent 14 years at Genzyme, where she ultimately became Sr. Vice President and Chief Patent Counsel. In that role, she was responsible for providing strategic guidance and IP advice for major commercial and research transactions as well as for developing and implementing strategies to procure, license, defend and enforce Genzyme’s worldwide intellectual property. Upon Genzyme’s acquisition by Sanofi, Maggie became Vice President and Chief Patent Counsel at Sanofi Pasteur, where she was responsible for leading IP attorneys and agents in the U.S., Canada, France and India. In 2014, Maggie became an independent IP consultant, providing strategic advice related to IP portfolio development, commercial transactions and potential and ongoing patent and trade secret disputes.
Neil K. Warma
Neil K. Warma, MBA, was appointed to the Board of Directors in May 2021. Neil Warma has been a successful healthcare entrepreneur for over 25 years having founded, managed and advised numerous biotech and pharmaceutical companies across the globe. Currently, Mr. Warma is the CEO/General Manager of I-Mab Biopharma U.S., (Nasdaq:IMAB) a publicly traded global biopharmaceutical company with offices and research labs in China (Shanghai, Beijing) and the U.S. (San Diego, Gaithersburg) that focuses on developing and commercializing novel immuno oncology drugs. Previously, as President and CEO of Opexa Therapeutics (Nasdaq:OPXA), a publicly traded biopharmaceutical company, Mr. Warma led the turnaround and rebuilding of the company’s cell therapy platform and oversaw its advance through clinical development in autoimmune and orphan diseases, expansion into China and its eventual merger with Acer Therapeutics (Nasdaq:ACER). Prior to Opexa, he was CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.
William W. Wyman began his career at the management consulting firm Booz Allen and Hamilton. After working for the firm in New York, Duesseldorf Germany, Athens Greece, and Dallas Texas, he returned to New York to become the President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors. Subsequently, Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. Now part of Marsh & McLennan, the firm employs 3,700 professionals in 26 countries.
Mr Wyman has served as director to more than eighteen public and private companies, mostly smaller companies in the technology and finance sectors. He also has served as an advisor to several private equity partnerships.
Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School. He also served in the U.S. Navy for four years. He resides in Hanover, NH.
Harnessing the power of precision medicine to conquer Alzheimer’s disease.